Who suits a ChondroFiller hip injection

Whether a ChondroFiller injection is suitable for your hip depends less on how much pain you are in and more on the nature and location of the cartilage loss. The key question a specialist needs to answer is whether your damage is focal and contained — a discrete patch of worn cartilage — or whether it reflects widespread joint degeneration that has already narrowed the joint space significantly. These two presentations sit at opposite ends of the candidacy spectrum.

The patients who tend to be well matched for this treatment are active adults, typically in their 40s to mid-60s, whose hip cartilage has been damaged by a specific cause: femoroacetabular impingement (FAI) or a prior injury. In both situations, a relatively bounded area of the joint surface is affected while the surrounding cartilage remains reasonably intact. Younger patients with an isolated post-traumatic lesion are also strong candidates — a 2025 case report documented complete pain relief and full range of movement in a 32-year-old following ChondroFiller injection to the femoral head without any additional surgical procedure.

Two practical gateway factors are worth knowing before any imaging takes place. First, the joint space on X-ray should still be preserved — significant narrowing is a disqualifier at the outset. Second, candidates will usually have already worked through an adequate course of conservative management — physiotherapy, analgesia, and activity modification — without achieving satisfactory relief. If both apply, the next step is imaging to assess whether the defect itself meets the specific size and grade criteria that determine suitability.

The defect criteria that guide eligibility

Three imaging thresholds — defect grade, defect size, and overall joint health — work together to determine whether the hip is a viable target for the ChondroFiller injection.

The defect itself needs to be ICRS Grade III or IV: full- or near-full-thickness cartilage loss affecting between 2 cm² and 6 cm² of the joint surface, whether on the acetabulum or the femoral head. Below that size range there may be insufficient structural need; above it, the scaffold cannot reliably fill the cavity in a single treatment.

Equally important is the state of the wider joint. Tönnis grade is a straightforward X-ray measure of hip joint narrowing and bone change — a Tönnis grade of 0 or 1 means the joint space is broadly preserved, while grade 2 or 3 indicates advancing osteoarthritis. This matters enormously for outcomes. In the Mazek 2021 prospective cohort (26 patients with FAI-related acetabular lesions), those with Tönnis grades 2–3 fared poorly; by contrast, 17 of 21 patients in the focal-lesion group with lower Tönnis grades achieved good or excellent results at three to five years, with MRI-confirmed cartilage healing. Kellgren-Lawrence grades I–III on plain X-ray and VAS or WOMAC symptom scores are used alongside Tönnis grading to build a complete clinical picture.

Containment is the final geometrical factor. A well-bordered crater — where healthy cartilage rim surrounds the defect — holds the scaffold in place far more reliably than an uncontained 'shoulder' lesion of the same size.

Pre-treatment MRI is not optional. It is the only way to confirm that thinning is focal rather than diffuse, and any clinic that proposes injection without first reviewing imaging should be treated as a warning sign.

How ultrasound-guided placement works in the hip

On the day of treatment, the procedure takes place in a clinic room rather than an operating theatre. No general anaesthetic is required — a local anaesthetic is applied to the entry site, and the clinician guides a fine needle into the hip joint using real-time ultrasound imaging to confirm precise needle placement before the collagen scaffold is introduced.

Once inside the joint, the injectable collagen material gels in situ, conforming to the contours of the defect. At that point it begins functioning as a chemotactic matrix: the scaffold signals to progenitor cells in the surrounding synovium and subchondral bone, drawing them into the lesion to initiate endogenous cartilage repair. This process — acellular matrix-induced chondrogenesis — is what separates ChondroFiller injection from viscosupplementation or a corticosteroid: hyaluronic acid lubricates; corticosteroid dampens inflammation; ChondroFiller provides a structural scaffold that actively recruits the patient's own cells.

Because the product is acellular and ready-made, the entire treatment is completed in a single session. There is no donor-site harvest, no cell culture period, and no second procedure. Patients leave the same day.

What the evidence shows for hip outcomes

The most directly relevant published validation for the ultrasound-guided injection route comes from a 2023 real-life study of 44 patients with Kellgren-Lawrence grade I or II hip osteoarthritis who received intraarticular collagen scaffold injections placed under ultrasound guidance. The study recorded statistically significant improvements in both VAS pain scores (p<0.0001) and overall WOMAC scores at one and three months, with zero adverse events across the cohort — supporting both the efficacy and the safety profile of this delivery route.

Quantified functional outcomes from hip-specific published series provide additional reference points. Harris Hip Score improvements of approximately +33 points and MOCART MRI regeneration scores in the range of 70–87 have been reported, with MOCART values in that bracket indicating hyaline-like tissue formation rather than the fibrocartilage associated with microfracture. The MOCART score tracks morphological tissue quality on MRI and offers a measure of how well matrix-induced chondrogenesis has produced structurally coherent repair tissue within the defect. Across published series, symptom relief is achieved in roughly 70–85% of treated patients, with a reoperation rate of approximately 3–8%.

A 2025 case report extended the evidence base to an isolated osteochondral defect of the femoral head — a 15×5 mm lesion on the superoanterior weight-bearing dome in a 32-year-old male. ChondroFiller application without supplementary microfracture achieved complete pain relief and full range of movement at follow-up, supporting the scaffold's capacity to support the body's own repair process without disrupting underlying bone.

Published data on the hip are more limited than for the knee, and large randomised controlled trials are absent. The available evidence rests primarily on single-centre cohorts. These are genuine constraints, and suitability remains a decision made on individual imaging and clinical grounds.

When the ChondroFiller hip injection is not suitable

Several conditions place ChondroFiller hip injection firmly out of reach, and recognising them early avoids unnecessary consultation time.

As covered when discussing the imaging thresholds, a Tönnis grade of 2 or above — or diffuse, generalised cartilage loss rather than a contained focal lesion — disqualifies a patient at the first gate; no further criteria need to be assessed.

Beyond that joint-integrity threshold, the following are absolute exclusions:

• Inflammatory arthritis (rheumatoid arthritis and other autoimmune joint diseases). The scaffold relies on the patient's own progenitor cells migrating into the defect; an autoimmune environment actively attacks joint tissue and disrupts that repair process from the outset.
• Metabolic arthropathy — including gout and pseudogout. Crystal deposition causes a different category of joint damage that a collagen scaffold cannot address and may aggravate.
• Developmental dysplasia of the hip (DDH). Where the acetabulum has not formed correctly, cartilage damage is a consequence of an underlying structural problem. Filling a focal defect without correcting the anatomy does not resolve the root cause and is unlikely to produce durable results.
• Known collagen allergy. ChondroFiller is a murine-derived Type I collagen product; hypersensitivity is an absolute contraindication.

In clinical practice, the most frequent reason patients are turned away is pre-existing osteoarthritis identified on pre-treatment imaging — which is why MRI review before any assessment is non-negotiable.

Getting a hip candidacy assessment in London

An assessment at London Cartilage Clinic begins with imaging review — if a recent MRI (within 12–18 months) is already available, bringing that to the first appointment allows the clinical team to work through the candidacy criteria covered in this article straight away. Where no MRI exists, one can be arranged as part of the assessment pathway. The consultation then moves to a physical examination, a review of symptom history and what non-operative management has already been tried, and a discussion of whether the ultrasound-guided injection pathway is appropriate for the specific defect identified. Professor Paul Y. F. Lee leads ChondroFiller delivery in the UK; precise, image-guided placement is a technical variable that directly influences how well the scaffold sits within the defect.

Patients attending for the first time are advised to bring any existing imaging, a brief written record of previous treatments, and a note of current pain scores if they have been tracking them. Assessments are available at the London Cartilage Clinic on Harley Street; bookings can be made at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
3. [3] Ultrasound guided injection with Collagen-based Medical Device: real-life evaluation of efficacy and safety in hip osteoarthritis. (2023). https://doi.org/10.11152/mu-4242 https://doi.org/10.11152/mu-4242